SEARCH

SEARCH BY CITATION

References

  • 1
    Harper DM,Franco EL,Wheeler CM,Moscicki AB,Romanowski B,Roteli-Martins CM,Jenkins D,Schuind A,Costa Clemens SA,Dubin G. Sustained efficacy up to 4–5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 124755.
  • 2
    Villa LL,Costa RL,Petta CA,Andrade RP,Ault KA,Giuliano AR,Wheeler CM,Koutsky LA,Malm C,Lehtinin M,Skjeldestad FE,Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 2718.
  • 3
    Muñoz N,Bosch FX,Castellsagué X,Diaz M,de Sanjosé S,Hammouda D,Shah KV,Meijer CJLM. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 27885.
  • 4
    Clifford GM,Smith JS,Plummer M,Muñoz N,Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 6373.
  • 5
    Clifford GM,Smith JS,Aguado T,Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 1015.
  • 6
    Ferlay J,Bray F,Pisani P,Parkin DM. Globocan 2002: incidence, mortality and prevalence worldwide [CD-ROM]. Lyon, France: International Agency for Research on Cancer, 2004.
  • 7
    Clifford GM,Rana RK,Franceschi S,Smith JS,Gough G,Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 115764.
  • 8
    Franceschi S,Clifford GM. Re: a study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 9389.
  • 9
    Woodman CB,Collins S,Rollason TP,Winter H,Bailey A,Yates M,Young LS. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 2003; 361: 403.
  • 10
    Iftner T,Villa LL. Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr 2003; 31: 808.
  • 11
    Walboomers JM,Jacobs MV,Manos MM,Bosch FX,Kummer JA,Shah KV,Snijders PJF,Peto J,Meijer CJLM,Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.